Maternal Fatal Medicine
A maternal-fatal medicine specialist is a doctor who helps take care of women having complicated or high-risk pregnancies. Being pregnant with twins is considered a high-risk pregnancy so it's likely that an MFM specialist will be part of your medical team. These doctors are obstetricians who also completed 3 extra years of training in high-risk pregnancy. They are also called primatologists or high-risk pregnancy doctors
Reproductive Medicine
Reproductive Medicine is a branch a medicine that deals with the reproduction were the speakers will be presenting the preventive measures, diagnosis methods and the steps to manage reproductive problems with the motto to improve or maintaining reproductive health and allowing people to have their children at a time of their choosing. The doctors and the experts trained in reproductive endocrinology, infertility, sexual medicine and andragogy can join us.
Maternal Mortality
The leading medical causes of maternal mortality include cardiovascular disease, infection, and common obstetric complications such as haemorrhage, and vary by timing relative to the end of pregnancy: Maternal mortality and severe maternal morbidity, particularly among women
Maternal fatal medicine international conference 2021|maternal fatal medicine 2021 worldwide |maternal fatal medicine webinar 2021|maternal mortality international conference 2021
Cosmetic Gynaecology
Cosmetic gynaecology, a field which has garnered substantial attention over recent years, lacks a universally accepted nomenclature. The aim of this systematic review is to evaluate techniques, outcome measures reported, and adverse events in patients undergoing cosmetic gynaecology procedures and offer recommendations to improve reporting metrics.
Reproductive medicine international conference 2021| reproductive medicine 2021 | reproductive medicine worldwide 2021| reproductive international conference 2021|maternal mortality conference 2021
Menopause
Menopause is the biological process through which a woman halt to be fertile or menstruate. It is a normal part of life and is not referred a disease or a condition and last for 50 years in women. Different treatments for menopause-related disorders and symptoms include advice for lifestyle, hormone replacement therapy, herbal treatments, other complementary therapeutics and antidepressants can be discussed in this track.
Maternal fatal medicine international conference 2021|maternal fatal medicine 2021 worldwide |maternal fatal medicine webinar 2021|cosmetic gynaecology international conference 2021
Gynecologic anesthesia
Although important reductions in aesthesia-related maternal mortality have occurred in the past 5 decades, a greater risk (1.7 times) of maternal death is still witnessed with the use of general versus regional aesthesia. Aesthetic care for gynaecologic surgery requires an understanding of gender-related differences in physiology, including sensitivity to pain, and pharmacodynamics, including responses to aesthetic drugs; such differences ultimately may affect patient outcomes and satisfaction. The different procedures and importance of aesthesia can be discussed and can present in our conference.
Maternal fatal medicine international conference 2021|maternal fatal medicine 2021 worldwide |maternal fatal medicine webinar 2021|cosmetic gynaecology international conference 2021
Gynecological imaging
This chapter summarizes the diagnostic performance (sensitivity, specificity, positive and negative likelihood ratios) of ultrasound, computed tomography, and magnetic resonance imaging in the diagnosis of various gynaecological diseases and tumours. Positron emission tomography is not discussed. Imaging in infertility, in the diagnosis of Mullein duct anomalies and in gynaecological oncology (staging of gynaecological cancers, diagnosis of recurrence of gynaecological cancer, diagnosis of trophoblastic tumours) is not dealt with. Ultrasound is the first-line imaging method for discrimination between viable intrauterine pregnancy, miscarriage and tubal pregnancy in women with bleeding and/or pain in early pregnancy
MARKETING
A Gynaecologist and Obstetrician provide care to women from the time they get pregnant and right through pregnancy till after the baby is born. OB-GYNs are essentially specialists in two different but related fields – obstetrics and gynaecology. While gynaecology deals with a broad spectrum of issues relevant to women and their reproductive health, obstetrics deals with delivering and monitoring the health of new-borns. To be able to address all the health issues that affect women, many women’s health specialists choose to practice obstetrics and gynaecology simultaneously.
The global women health market was esteemed at USD 36.5 billion out of 2016 and is expected to develop at a CAGR of 3.9% over the conjecture time frame. Expanding female geriatric populace, undesirable way of life, positive government approaches and activities by private associations, alongside the presentation of new medicines for ladies are factors in charge of development. On the idea of application, the women’s health market has been segmental into biological time pathology, sterility, Adenomyosis, contraceptives, menopause, Polycystic Ovary Syndrome ,Cervical Intraepithelial Neoplastic, Endometriosis, Fibroids, Human papillomavirus, Infertility, Menopause, Ovarian failure, Pelvic inflammatory disease,
Women’s health is a perspective of prevention and treatment that looks at health concerns unique to females. Even though slightly more than half of the US population is female, medical research historically has neglected the health needs of women, other than reproductive issues. Recently there have been major changes in government and private support of women’s health research in policies, regulations, and the organization of research efforts. In a recent Institute of Medicine (IOM) report, the Washington DC-based institute found that women’s health research has contributed to significant progress over the past 20 years in lessening the burden of disease and reducing deaths from some conditions for women, while other conditions have seen only moderate change or even little or no change. Gaps remain, both in research areas and in the application of results to benefit women in general and across multiple population groups.